Article
Multidisciplinary Sciences
Taiwo O. Abimbola, Michelle Van Handel, Yunfeng Tie, Lijing Ouyang, Noele Nelson, John Weiser
Summary: The study evaluates the cost-effectiveness of hepatitis A vaccination in persons with HIV (PWH) in the United States. Full implementation of the Advisory Committee on Immunization Practices (ACIP) recommendation leads to a significant reduction in hepatitis A cases among PWH. The cost per case averted depends on the type of vaccine used, ranging from $48,000 to $130,000.
Article
Immunology
David C. Boettiger, Anthony T. Newall, Andrew Phillips, Eran Bendavid, Matthew G. Law, Lene Ryom, Peter Reiss, Amanda Mocroft, Fabrice Bonnet, Rainer Weber, Wafaa El-Sadr, Antonella D'Arminio Monforte, Stephane Wit, Christian Pradier, Camilla Hatleberg, Jens Lundgren, Caroline Sabin, James G. Kahn, Dhruv S. Kazi
Summary: This study evaluated the cost-effectiveness of pravastatin and pitavastatin for the primary prevention of atherosclerotic cardiovascular disease among people living with HIV (PLHIV) in the United States. It found that pravastatin was more cost-effective compared to no statin use, while pitavastatin may be more costly but more effective than pravastatin.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2021)
Article
Genetics & Heredity
Gregory F. Guzauskas, Shangqing Jiang, Shawn Garbett, Zilu Zhou, Scott J. Spencer, Susan R. Snyder, John A. Graves, Marc S. Williams, Jing Hao, Josh F. Peterson, David L. Veenstra
Summary: This study evaluated the cost-effectiveness of population-wide genomic screening for Lynch syndrome (LS) in an unselected US population and found that LS screening may be cost-effective for younger patient populations. However, further reductions in testing costs and the inclusion of LS testing in broader screening panels are needed to achieve high cost-effectiveness.
GENETICS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Anne M. Neilan, Raphael J. Landovitz, Mylinh H. Le, Beatriz Grinsztejn, Kenneth A. Freedberg, Marybeth McCauley, Nattanicha Wattananimitgul, Myron S. Cohen, Andrea L. Ciaranello, Meredith E. Clement, Krishna P. Reddy, Emily P. Hyle, A. David Paltiel, Rochelle P. Walensky
Summary: The study found that although CAB-LA offers more benefits over F/TDF, effective oral PrEP limits the additional price society should be willing to pay for CAB-LA.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Yi-Hsuan Chen, Chi-Tai Fang, Ming-Chieh Shih, Kuan-Yin Lin, Shu-Sen Chang, Zong-Tai Wu, Yu-Yao Lee, Chang-Hsun Chen
Summary: The study found that routine HIV testing was associated with lower rates of late diagnosis, HIV-related mortality, and all-cause mortality compared to nonroutine testing based on individual risk assessment.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Johan Lyth, Emma Svennberg, Lars Bernfort, Mattias Aronsson, Viveka Frykman, Faris Al-Khalili, Leif Friberg, Marten Rosenqvist, Johan Engdahl, Lars-Ake Levin
Summary: This study aimed to evaluate the cost-effectiveness of population-based screening for atrial fibrillation (AF) using clinical outcomes. The analysis showed that the screening intervention group had higher gained life years and gained quality-adjusted life years at a lower cost.
EUROPEAN HEART JOURNAL
(2023)
Article
Immunology
Anne M. Neilan, Alexander J. B. Bulteel, Sybil G. Hosek, Julia H. A. Foote, Kenneth A. Freedberg, Raphael J. Landovitz, Rochelle P. Walensky, Stephen C. Resch, Pooyan Kazemian, A. David Paltiel, Milton C. Weinstein, Craig M. Wilson, Andrea L. Ciaranello
Summary: The study shows that for high-risk YMSM in the US, HIV screening every 3 months is more clinically effective and cost-effective compared to screening at less frequent intervals.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Clinical Neurology
Melike Yildirim, Bradley N. Gaynes, Pinar Keskinocak, Brian W. Pence, Julie Swann
Summary: The study aimed to determine the cost-effectiveness of depression screening schedules, showing that routine screening is cost-effective for all age groups of females and young, middle-aged males.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Medicine, General & Internal
Marika M. Cusick, Rebecca L. Tisdale, Glenn M. Chertow, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
Summary: Adding SGLT2 inhibitors to CKD screening can be cost-effective, with a one-time screening at age 55 having an ICER of $86,300 per QALY gained, reducing the incidence of kidney failure. Screening every 10 years from age 35 to 75 costs less than $100,000 per QALY gained.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Grace A. McComsey, Melissa Lingohr-Smith, Rachel Rogers, Jay Lin, Prina Donga
Summary: This study examined adherence to ART regimens among patients with HIV-1 in the US and found that a majority of patients had suboptimal adherence, with the highest adherence in the West region.
ADVANCES IN THERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Rikke Sogaard, Axel Cosmus Pyndt Diederichsen, Lars M. Rasmussen, Jess Lambrechtsen, Flemming H. Steffensen, Lars Frost, Kenneth Egstrup, Grazina Urbonaviciene, Martin Busk, Jes S. Lindholt
Summary: A recent trial suggests that screening for cardiovascular disease in men may decrease all-cause mortality. This study evaluates the cost effectiveness of such screening and finds that comprehensive screening is cost effective compared to no screening.
EUROPEAN HEART JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Scott J. Spencer, Laney K. Jones, Gregory F. Guzauskas, Jing Hao, Marc S. Williams, Josh F. Peterson, David L. Veenstra
Summary: Population-wide FH genomic screening is not cost-effective at current willingness to pay thresholds, but reducing test costs, screening at younger ages, or including FH within broader multiplex screening panels may improve clinical and economic value.
JOURNAL OF CLINICAL LIPIDOLOGY
(2022)
Article
Medicine, General & Internal
Iakovos Toumazis, Pianpian Cao, Koen de Nijs, Mehrad Bastani, Vidit Munshi, Mehdi Hemmati, Kevin ten Haaf, Jihyoun Jeon, Martin Tammemagi, G. Scott Gazelle, Eric J. Feuer, Chung Yin Kong, Rafael Meza, Harry J. de Koning, Sylvia K. Plevritis, Summer S. S. Han
Summary: In their 2021 update, the USPSTF emphasized the need for further research on the benefits and harms of risk model-based lung cancer screening strategies. This comparative modeling analysis found that risk model-based screening strategies were more cost-effective than the USPSTF recommendation, with a 6-year risk threshold of 1.2% or greater being the most cost-effective.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Medicine, General & Internal
Gregory F. Guzauskas, Shawn Garbett, Zilu Zhou, Jonathan S. Schildcrout, John A. Graves, Marc S. Williams, Jing Hao, Laney K. Jones, Scott J. Spencer, Shangqing Jiang, David L. Veenstra, Josh F. Peterson
Summary: The cost-effectiveness of simultaneous genomic screening for Lynch syndrome (LS), hereditary breast and ovarian cancer syndrome (HBOC), and familial hypercholesterolemia (FH) in the U.S. population is estimated using a decision analytic Markov model. Results show that screening individuals younger than 40 years can reduce cancer and cardiovascular disease incidence, improve quality-adjusted survival, but at a relatively high cost.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Immunology
Namrata Prasad, Charles Stoecker, Wei Xing, Bo-Hyun Cho, Andrew J. Leidner, Miwako Kobayashi
Summary: Although PCV13 has reduced the incidence of pneumococcal disease, there is still a considerable burden. PCV15, a new vaccine, includes additional serotypes compared to PCV13. Replacing PCV13 with PCV15 and providing a supplementary dose to fully vaccinated children could have significant health benefits, cost saving, but also additional costs.